Effects of Exergames and Resistance Training
- Conditions
- CognitionMoodFrailtyMobilitySacropenia
- Interventions
- Other: exergames and resistance trainingOther: Resistance training
- Registration Number
- NCT05920577
- Lead Sponsor
- Hong Kong Metropolitan University
- Brief Summary
Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. Sacropenia and impaired cognitive function are two major contributors to frailty. This study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.
- Detailed Description
Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. The prevalence rates of frailty varies across countries, and the pooled estimates of prevalence rates of 52.3% and 40.2% of frailty and prefrailty were reported among nursing home residents respectively. Previous studies also revealed that frailty is predictive for various adverse health outcomes.
Sacropenia is a major etiologic risk factor to frailty. It refers to an age-related generalised muscle disorder featuring with loss of muscle mass and function5. Talar et al systematically reviewed and meta-analysed 25 randomised controlled trials (RCTs) using resistance training among 2,267 older people (age \>65 years) with pre-sarcopenia, sarcopenia, pre-frailty or frailty. It was revealed that, compared to control, resistance training with at least 8 weeks intervention period had small to large effects in improving handgrip strength, lower-limb strength, agility, gait speed, postural stability, functional performance, fat mass and muscle \[Effect size (ES) = 0.29 - 0.93, p \<0.001 to = 0.007\].
Cognitive impairment is another major risk factor for declined frailty status among prefrail older people. Non-frail older people are known to have better performance on cognitive status, including processing speed, executive function, attention and working memory, immediate memory and delayed memory (g = 0.320 to 0.64), than frail older people. Ample research evidence suggested that cognition predicts the incidence of frailty.
Exergaming is a fast growing research trend in gerontechnology and several commercial exergaming consoles, such as the Xbox system (including Xbox One and Xbox 360) and Nintendo Will (Wii Sports and Wii Fit), are available. Ogawa et al systematically reviewed 7 clinical trials (5 RCTs and 2 uncontrolled studies) and revealed that exergaming could improve cognitive functions, including executive function, process speed and reaction time, of older people. Moreover, a recent RCT revealed that, compared with the combined use of exercise (resistance, aerobic and balance training), a 12 week Kinect-based exergaming could better improve the global cognition \[F(1, 44) = 5.277, p = 0.026\] as measured by the Montreal Cognitive Assessment of community-frail older people. The Kinect-based group (n = 25) also demonstrated significant improvement in verbal (p \< 0.05) and working (p \< 0.05) memory post-intervention but the combined exercise group (n = 21) did not.
Given that sacropenia and impaired cognitive function are 2 major contributors to frailty; and exergaming and resistance training are effective treatments in improving the cognitive function and sacropenia of older people respectively, this study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- living in a nursing home
- fulfilled 1, 2 or 3 Fried Criteria of frailty
- score ≥7 of 10 on the Chinese version of the Abbreviated Mental Test
- able to follow the instructions of assessment and intervention
- involved in any drug or other clinical trials
- having any additional medical conditions (such as epilepsy)
- unable to walk independently without the use of walking aids
- having any other conditions that will hinder the assessment and intervention (e.g.,visual/audio impairment could not be corrected by glasses/hearing aids etc).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Exergames and resistance training group exergames and resistance training Participants will receive exergaming and resistance training programme over a period of 12 weeks Resistance training group Resistance training Participants will receive resistance training programme over a period of 12 weeks
- Primary Outcome Measures
Name Time Method Change from baseline muscle strength at 24 weeks, higher score means better muscle strength T5: 3 months follow up (week 24) Will be assessed using a handheld dynamometer
Muscle quantity, higher score means better muscle quantity T1: baseline (before the study begins) Will be assessed using a bioelectrical impedance measurement
Change from baseline muscle quantity at 6 weeks, higher score means better muscle quantity T2: mid-intervention (week 6) Will be assessed using a bioelectrical impedance measurement
Change from baseline muscle quantity at 12 weeks, higher score means better muscle quantity T3: post-intervention (week 12) Will be assessed using a bioelectrical impedance measurement
Change from baseline muscle quantity at 16 weeks, higher score means better muscle quantity T4: 1 month follow up (week 16) Will be assssed using a bioelectrical impedance measurement
Change from baseline muscle quantity at 24 weeks, higher score means better muscle quantity T5: 3 months follow up (week 24) Will be assssed using a bioelectrical impedance measurement
Change from baseline muscle strength at 12 weeks, higher score means better muscle strength T3: post-intervention (week 12) Will be assessed using a handheld dynamometer
Change from baseline muscle strength at 16 weeks, higher score means better muscle strength T4: 1 month follow up (week 16) Will be assessed using a handheld dynamometer
Change from baseline lower extremity functions at 6 weeks, score ranged from 0-12, higher scores mean better lower extremity functions T2: mid-intervention (week 6) Will be assessed using the Short Physical Performance Battery
Muscle strength, higher score means better muscle strength T1: baseline (before the study begins) Will be assessed using a handheld dynamometer
Change from baseline muscle strength at 6 weeks, higher score means better muscle strength T2: mid-intervention (week 6) Will be assessed using a handheld dynamometer
Change from baseline lower extremity functions at 12 weeks, score ranged from 0-12, higher scores mean better lower extremity functions T3: post-intervention (week 12) Will be assessed using the Short Physical Performance Battery
Change from baseline lower extremity functions at 24 weeks, score ranged from 0-12, higher scores mean better lower extremity functions T5: 3 months follow up (week 24) Will be assessed using the Short Physical Performance Battery
Lower Extremity functions, score ranged from 0-12, higher scores mean better lower extremity functions T1: baseline (before the study begins) Will be assessed using the Short Physical Performance Battery
Change from baseline lower extremity functions at 16 weeks, score ranged from 0-12, higher scores mean better lower extremity functions T4: 1 month follow up (week 16) Will be assessed using the Short Physical Performance Battery
- Secondary Outcome Measures
Name Time Method Mobility, longer time means worse functional mobility T1: baseline (before the study begins) Will be assessed using the Timed Up and Go Test
Change from baseline mobility at 12 weeks, longer time means worse functional mobility T3: post-intervention (week 12) Will be assessed using the Timed Up and Go Test
Change from baseline mobility at 16 weeks, longer time means worse functional mobility T4: 1 month follow up (week 16) Will be assessed using the Timed Up and Go Test
Change from baseline mobility at 24 weeks, longer time means worse functional mobility T5: 3 months follow up (week 24) Will be assessed using the Timed Up and Go Test
Frailty, score range 0 to 9, higher score means higher level of frailty T1: baseline (before the study begins) Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Change from baseline frailty at 12 weeks, score range 0 to 9, higher score means higher level of frailty T3: post-intervention (week 12) Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Cognitive function, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition T1: baseline (before the study begins) Will be assessed using the Montreal Cognitive Assessment (HK version)
Change from baseline frailty at 6 weeks, score range 0 to 9, higher score means higher level of frailty T2: mid-intervention (week 6) Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Change from baseline cognitive function at 6 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition T2: mid-intervention (week 6) Will be assessed using the Montreal Cognitive Assessment (HK version)
Change from baseline cognitive function at 16 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition T4: 1 month follow up (week 16) Will be assessed using the Montreal Cognitive Assessment (HK version)
Change from baseline cognitive function at 24 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition T5: 3 months follow up (week 24) Will be assessed using the Montreal Cognitive Assessment (HK version)
Change from baseline frailty at 24 weeks, score range 0 to 9, higher score means higher level of frailty T5: 3 months follow up (week 24) Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Change from baseline sarcopenia at 16 weeks, score ranged from 0 to 20, lower score means lower risk T4: 1 month follow up (week 16) Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Change from baseline cognitive function at 12 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition T3: post-intervention (week 12) Will be assessed using the Montreal Cognitive Assessment (HK version)
Change from baseline frailty at 16 weeks, score range 0 to 9, higher score means higher level of frailty T4: 1 month follow up (week 16) Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Change from baseline sarcopenia at 24 weeks, score ranged from 0 to 20, lower score means lower risk T5: 3 month follow up (week 16) Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Change from baseline mobility at 6 weeks, longer time means worse functional mobility T2: mid-intervention (week 6) Will be assessed using the Timed Up and Go Test
Sarcopenia, score ranged from 0 to 20, lower score means lower risk T1: baseline (before the study begins) Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
Change from baseline sarcopenia at 6 weeks, score ranged from 0 to 20, lower score means lower risk T2: mid-intervention (week 6) Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Change from baseline sarcopenia at 12 weeks, score ranged from 0 to 20, lower score means lower risk T3: post-intervention (week 12) Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
Trial Locations
- Locations (1)
Jockey club Institute of Health
🇭🇰Ho Man Tin, Hong Kong